Bio-Rad Laboratories, Inc. (BIO) Stock Analysis

Company Overview

Bio-Rad Laboratories, Inc. operates as a developer, manufacturer, and distributor of life science research and clinical diagnostic products, serving markets across the United States, Europe, Asia, Canada, Latin America, and internationally. The company functions within the Healthcare sector, specifically the Medical Devices industry, where it supplies essential tools and reagents for scientific research and patient diagnostics. Bio-Rad Laboratories, Inc. maintains a market capitalization of $7.15B and generates annual revenue of $2.58B, supported by a workforce of 7,450 employees. These valuation and revenue figures indicate that the company holds a substantial position in the medical devices market, reflecting significant scale in its operations across the Life Science and Clinical Diagnostics segments.

Financial Health

The company reports a Trailing Twelve Months (TTM) revenue of $2.58B with a corresponding net income of $759.90M and an EBITDA of $431.60M. The gap between the $2.58B revenue and the $759.90M net income reveals a cost structure where operating expenses and taxes consume a significant portion of top-line growth, leaving $1.82B in costs behind the profit line. Free cash flow stands at $256.55M, which provides the company with substantial financial flexibility to fund operations, reduce debt, or invest in R&D without relying on external financing. The gross margin of 52.0% indicates strong pricing power and cost control over the cost of goods sold, while the operating margin of 8.9% reflects the efficiency of the broader operational structure. The profit margin of 29.4% demonstrates the company's ability to convert a large share of revenue into bottom-line earnings after all expenses. Regarding liquidity and leverage, the company holds $1.54B in cash against $1.38B in debt, resulting in a debt-to-equity ratio of 18.58 which suggests a leveraged balance sheet relative to equity. The current ratio of 5.62 indicates robust short-term liquidity, showing that current assets are more than five times current liabilities. Return on Equity is 10.8% while Return on Assets is 1.7%, revealing that management generates higher returns relative to shareholder equity compared to the total asset base.

Valuation Assessment

The trailing P/E ratio is 9.52 while the forward P/E is 23.42, implying that the market expects earnings growth to accelerate significantly in the future to justify the higher multiple. The price-to-book ratio of 0.96 indicates that the stock trades at a discount to its book value, suggesting the market may be undervaluing the company's tangible assets or anticipating challenges in future profitability. The price-to-sales ratio of 2.77 and an EV/EBITDA of 16.21 offer alternative perspectives that suggest the stock is priced moderately relative to its sales volume and earnings before interest, taxes, depreciation, and amortization. The 52-week high is $343.12 and the 52-week low is $211.43, providing the trading range within which the stock has fluctuated over the past year. The beta value of 1.20 indicates that the stock's price volatility is 20% higher than the broader market, meaning it tends to move more aggressively than the general index.

Growth & Income

Revenue growth year-over-year is 3.9%, whereas earnings growth year-over-year is listed as N/A, indicating that earnings performance is not currently quantifiable in the provided data or is subject to specific adjustments not detailed here. Because earnings growth is not explicitly provided as a positive percentage, the relationship between revenue and earnings cannot be definitively characterized as one growing faster than the other based solely on the available figures. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests its earnings into growth initiatives rather than distributing cash to shareholders. This reinvestment strategy aligns with the company's focus on R&D and market expansion within the life science and diagnostic sectors. The overall profile presents a growth-oriented financial structure with no current income generation through dividends, relying instead on capital appreciation and operational expansion for shareholder value.